Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients

International Immunopharmacology

Volumn 13, Issue 1, 2012, Pages 93-100

  Tuettenberg, Jochen ^a   Seiz, Marcel ^b   Debatin, Klaus Michael ^c   Hollburg, Wiebke ^d   Von Staden, Michael ^d   Thiemann, Meinolf ^e   Hareng, Barbara ^e   Fricke, Harald ^e   Kunz, Claudia ^e  

^a SHG Klinikum Idar Oberstein   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Hämatologisch Onkologische Praxis Altona HOPA   (Germany)

^e APOGENIX GMBH   (Germany)

Author keywords

APG101; CD95; Glioblastoma; Pharmacodynamics; Pharmacokinetics; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; APG101; CXCL2 CHEMOKINE; DRUG ANTIBODY; FAS ANTIGEN; FC RECEPTOR; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OLIGODENDROGLIOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 84859508524     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.03.004     Document Type: Letter

References (9)

1. S. Nagata Fas ligand-induced apoptosis Annu Rev Genet 33 1999 29 55
2. P.H. Krammer CD95's deadly mission in the immune system Nature 407 2000 789 795
3. A. Strasser, P.J. Jost, and S. Nagata The many roles of FAS receptor signaling in the immune system Immunity 30 2009 180 192
4. M.E. Peter, P. Legembre, and B.C. Barnhart Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755 2005 25 36
5. K.M. Debatin, and P.H. Krammer Death receptors in chemotherapy and cancer Oncogene 23 2004 2950 2966
6. B.C. Barnhart, P. Legembre, E. Pietras, C. Bubici, G. Franzoso, and M.E. Peter CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells EMBO J 23 2004 3175 3185
7. M.E. Peter, R.C. Budd, J. Desbarats, S.M. Hedrick, A.O. Hueber, and M.K. Newell The CD95 receptor: apoptosis revisited Cell 129 2007 447 450
8. L. Chen, S.M. Park, A.V. Tumanov, A. Hau, K. Sawada, and C. Feig CD95 promotes tumour growth Nature 465 2010 492 496 including Green DR. A wolf in wolf's clothing. Nature 2010;465:433-4
9. S. Kleber, I. Sancho-Martinez, B. Wiestler, A. Beisel, C. Gieffers, and O. Hill Yes and PI3K bind CD95 to signal invasion of glioblastoma Cancer Cell 13 2008 235 248